Clinical context

In glaucoma, intraocular pressure reduction is important but remains a surrogate outcome. Clinical value also depends on preservation of the visual field and optic nerve, safety, the need for additional medication or surgery, and treatment adherence. Target pressure is individualized, so the same numerical change can carry different meaning at different disease stages and rates of progression.

What was studied

This multicenter pivotal study enrolled 318 adults with cataract and mild-to-moderate primary open-angle glaucoma. Medicated pressure was 24 mmHg or lower on 1–3 drugs; mean unmedicated diurnal pressure after washout was 22–34 mmHg. All underwent phacoemulsification with ELIOS excimer laser trabeculostomy. Without a concurrent control, effectiveness was compared with thresholds derived from phacoemulsification-only arms of other MIGS trials.

How the evidence was produced

A cohort study describes how outcomes are associated with an exposure or treatment in an observed clinical population. This design is useful for routine practice, uncommon events and longer follow-up, but it remains vulnerable to confounding by indication, baseline risk differences and missing data. An association should not automatically be interpreted as a causal effect.

Key result Baseline mean unmedicated diurnal pressure was 24.53 ± 2.51 mmHg. A reduction of at least 20% was achieved by 84.2% at 12 months and 76.1% at 24 months, exceeding performance goals of 79% and 68.5%, P=.0116 and P=.0018. Mean change was −8.17 ± 0.21 and −7.35 ± 0.22 mmHg, both P<.0001 against their thresholds. Mean pressure was 15.98 and 16.76 mmHg. At month 23, 82.0% used no hypotensive medication. No intraoperative adverse event occurred during ELIOS; endothelial-cell loss occurred early and stabilized from month 3 through month 24.

How to interpret the result

The study shows sustained reduction in washout pressure and medication burden in selected patients. Exceeding a historical goal is weaker than randomization against phacoemulsification alone: populations, washout and analysis rules may differ. ELIOS is a possible phaco-MIGS option, but superiority over another MIGS or standalone phacoemulsification is unproven. Selection depends on stage, target pressure, angle status, medication tolerance and follow-up.

The result should be understood as an estimate for the population studied, not a promise of an individual outcome. Statistical and clinical significance, absolute and relative effects, and prespecified and exploratory analyses should be distinguished. When several endpoints or subgroups are reported, the prespecified primary endpoint for which the study was designed usually provides the most reliable inference.

Clinical applicability

The findings can inform discussions about treatment sequence and burden. Before changing management, compare the study population with the patient in front of you, including glaucoma stage, baseline pressure, previous treatment, angle anatomy and rate of field loss. A pressure measurement does not replace structural and functional follow-up.

Limitations

The trial was nonrandomized and uncontrolled, with thresholds borrowed from other studies. Only mild-to-moderate POAG within specified pressure ranges was included, limiting extension to advanced or secondary glaucoma. Manufacturer participation and investigators linked to the device require careful conflict-of-interest review. The full paper should be checked for 24-month attrition, imputation and washout rules, completion of diurnal curves, adverse events, field and endothelial change, additional surgery and construction of the external performance goals.

Beyond the limitations acknowledged by the authors, confidence is affected by sample size, follow-up duration, missing data, choice of comparator and relevance of the outcomes to routine care. Uncommon complications may remain undetected even in a well-conducted study. External validity is reduced when participants, equipment or investigator expertise differ substantially from everyday settings.

What to verify in the source

In the full paper, verify the protocol, eligibility criteria, baseline group characteristics, primary endpoint definition, confidence intervals, adverse events and losses to follow-up. Funding, conflicts of interest, trial registration and consistency between the published analysis and the original plan deserve separate attention. The DOI or source link below provides access to the primary publication for this check.